IRGD peptides

Last updated

IRGD peptides
IRGD.svg
Clinical data
Routes of
administration
Intravenous
Pharmacokinetic data
Bioavailability 100%
Metabolism n/a
Elimination half-life 1-3 hours
Duration of action up to 24 hours
Excretion Renal (100%)
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
Molar mass (948.04 g/mol after conversion)

Internalizing RGD (iRGD) peptides are a class of 9-amino acid cyclic peptides containing an RGD sequence, which undergo internalization as discussed below. The prototypic iRGD peptide, shown in the image on the right (sequence: CRGDKGPDC; CAS 1392278-76-0), was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice. [1] The peptide was able to home to tumor tissues, but in contrast to standard RGD (arginylglycylaspartic acid) peptides, spread much more extensively into extravascular tumor tissue. It was later identified that this extravasation and transport through extravascular tumor tissue is due to the bifunctional action of the molecule: after the initial RGD-mediated tumor homing, another pharmacologic motif is able to manipulate tumor microenvironment, making it temporarily accessible to circulating drugs. [2] This second step is mediated through specific secondary binding to neuropilin-1 receptor, and subsequent activation of a trans-tissue pathway, dubbed the C-end Rule, or CendR pathway. [3]

Contents

Mechanism of action

The iRGD peptide homes to and penetrates tumors through a 3-step process. First, the RGD sequence motif mediates binding to αVβ3 and αVβ5 integrins that are expressed on tumor endothelial cells. Second, upon αV binding, a protease cleavage event is activated, revealing the C-terminal CendR motif (R/KXXR/K) of the peptide. Third, the CendR motif is now able to bind to neuropilin-1, activating an endocytotic/exocytotic transport pathway. [4] The pathway triggered by iRGD can be used for the enhanced transport of coupled and coadministered anti-cancer drugs into tumors. [3]

Uses

iRGD peptides have been shown to increase accumulation and penetration of anticancer drugs into tumors, but not into normal tissues – whether the drug is coupled to the peptide or given together with it. [5] iRGD-mediated increased penetration and anti-cancer efficacy have been demonstrated with a variety of anti-cancer small molecules, nanoparticles and antibodies. [6] Lisata Therapeutics Inc. is currently testing iRGD-based therapy called certepetide (aka LSTA1; CEND-1) in clinical studies in solid-tumor patients. [7] The U.S. Food and Drug Administration (FDA) awarded certepetide orphan drug status in 2019, and fast-track designation in 2020. [8]

Related Research Articles

<span class="mw-page-title-main">Tyrosine kinase</span> Enzyme

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to the tyrosine residues of specific proteins inside a cell. It functions as an "on" or "off" switch in many cellular functions.

<span class="mw-page-title-main">Tumor necrosis factor</span> Immune system messenger protein which induces inflammation

Tumor necrosis factor (TNF), formerly known as TNF-α, is a chemical messenger produced by the immune system that induces inflammation. TNF is produced primarily by activated macrophages, and induces inflammation by binding to its receptors on other cells. It is a member of the tumor necrosis factor superfamily, a family of transmembrane proteins that are cytokines, chemical messengers of the immune system. Excessive production of TNF plays a critical role in several inflammatory diseases, and TNF-blocking drugs are often employed to treat these diseases.

<span class="mw-page-title-main">Peptidomimetic</span> Class of compounds designed to mimic features of peptides

A peptidomimetic is a small protein-like chain designed to mimic a peptide. They typically arise either from modification of an existing peptide, or by designing similar systems that mimic peptides, such as peptoids and β-peptides. Irrespective of the approach, the altered chemical structure is designed to advantageously adjust the molecular properties such as stability or biological activity. This can have a role in the development of drug-like compounds from existing peptides. Peptidomimetics can be prepared by cyclization of linear peptides or coupling of stable unnatural amino acids. These modifications involve changes to the peptide that will not occur naturally. Unnatural amino acids can be generated from their native analogs via modifications such as amine alkylation, side chain substitution, structural bond extension cyclization, and isosteric replacements within the amino acid backbone. Based on their similarity with the precursor peptide, peptidomimetics can be grouped into four classes where A features the most and D the least similarities. Classes A and B involve peptide-like scaffolds, while classes C and D include small molecules.

<span class="mw-page-title-main">Mothers against decapentaplegic homolog 3</span> Protein-coding gene in humans

Mothers against decapentaplegic homolog 3 also known as SMAD family member 3 or SMAD3 is a protein that in humans is encoded by the SMAD3 gene.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

<span class="mw-page-title-main">Thrombospondin 1</span> Protein-coding gene in the species Homo sapiens

Thrombospondin 1, abbreviated as THBS1, is a protein that in humans is encoded by the THBS1 gene.

<span class="mw-page-title-main">Sanford Burnham Prebys</span> Non-profit medical research institute

Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focused on conducting basic and translational research. It’s primary research areas include cancer, neurodegeneration, diabetes, infectious diseases, inflammatory conditions, and childhood illnesses. Additionally, the institute specializes in stem cell research and the development of drug discovery technologies.

The IκB kinase is an enzyme complex that is involved in propagating the cellular response to inflammation, specifically the regulation of lymphocytes.

<span class="mw-page-title-main">IGFBP3</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 3, also known as IGFBP-3, is a protein that in humans is encoded by the IGFBP3 gene. IGFBP-3 is one of six IGF binding proteins that have highly conserved structures and bind the insulin-like growth factors IGF-1 and IGF-2 with high affinity. IGFBP-7, sometimes included in this family, shares neither the conserved structural features nor the high IGF affinity. Instead, IGFBP-7 binds IGF1R, which blocks IGF-1 and IGF-2 binding, resulting in apoptosis.

<span class="mw-page-title-main">LRP1</span> Mammalian protein found in Homo sapiens

Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) or cluster of differentiation 91 (CD91), is a protein forming a receptor found in the plasma membrane of cells involved in receptor-mediated endocytosis. In humans, the LRP1 protein is encoded by the LRP1 gene. LRP1 is also a key signalling protein and, thus, involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as neurodegenerative diseases, atherosclerosis, and cancer.

<span class="mw-page-title-main">S1PR1</span> Protein and coding gene in humans

Sphingosine-1-phosphate receptor 1, also known as endothelial differentiation gene 1 (EDG1) is a protein that in humans is encoded by the S1PR1 gene. S1PR1 is a G-protein-coupled receptor which binds the bioactive signaling molecule sphingosine 1-phosphate (S1P). S1PR1 belongs to a sphingosine-1-phosphate receptor subfamily comprising five members (S1PR1-5). S1PR1 was originally identified as an abundant transcript in endothelial cells and it has an important role in regulating endothelial cell cytoskeletal structure, migration, capillary-like network formation and vascular maturation. In addition, S1PR1 signaling is important in the regulation of lymphocyte maturation, migration and trafficking.

<span class="mw-page-title-main">Neuropilin 1</span> Protein-coding gene in the species Homo sapiens

Neuropilin-1 is a protein that in humans is encoded by the NRP1 gene. In humans, the neuropilin 1 gene is located at 10p11.22. This is one of two human neuropilins.

<span class="mw-page-title-main">MAP4K4</span> Protein-coding gene in the species Homo sapiens

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) – also known as hepatocyte progenitor kinase-like/germinal center kinase-like kinase (HGK) and Nck-interacting kinase (NIK) – is an enzyme, specifically a serine/threonine (S/T) kinase encoded by the MAP4K4 gene in humans.

<span class="mw-page-title-main">Erkki Ruoslahti</span>

Erkki Ruoslahti is a cancer researcher and distinguished professor at Sanford Burnham Prebys Medical Discovery Institute. He moved from Finland to the United States in 1976.

Transforming growth factor beta (TGF-β) is a potent cell regulatory polypeptide homodimer of 25kD. It is a multifunctional signaling molecule with more than 40 related family members. TGF-β plays a role in a wide array of cellular processes including early embryonic development, cell growth, differentiation, motility, and apoptosis.

<span class="mw-page-title-main">Arginylglycylaspartic acid</span> Chemical compound

Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. The discovery of RGD and elucidation of how RGD binds to integrins has led to the development of a number of drugs and diagnostics, while the peptide itself is used ubiquitously in bioengineering. Depending on the application and the integrin targeted, RGD can be chemically modified or replaced by a similar peptide which promotes cell adhesion.

<span class="mw-page-title-main">Short linear motif</span>

In molecular biology short linear motifs (SLiMs), linear motifs or minimotifs are short stretches of protein sequence that mediate protein–protein interaction.

Adenovirus varieties have been explored extensively as a viral vector for gene therapy and also as an oncolytic virus.

CendR is a position-dependent protein motif that regulates cellular uptake and vascular permeability through interaction with neuropilin-1. The CendR motif has a consensus (R/K)XX(R/K) and it is able to interact with its receptor only when the second basic residue is exposed at the C-terminus.

<span class="mw-page-title-main">Ga-68-Trivehexin</span> Contrast agent for cancer imaging

68Ga-Trivehexin is a radiotracer for positron emission tomography (PET), obtained by labeling the peptide conjugate Trivehexin with the a positron emitting radionuclide gallium-68 (68Ga). 68Ga-Trivehexin targets the cell surface receptor αvβ6-integrin, a heterodimeric transmembrane cell adhesion receptor whose primary natural ligand is latency associated peptide (LAP) in its complex with transforming growth factor beta 1. 68Ga-Trivehexin is applied for PET imaging of medical conditions associated with elevated αvβ6-integrin expression. As an activator of TGF-β1, αvβ6-integrin is often overexpressed in tumors and fibrosis tissues, which is why 68Ga-Trivehexin PET imaging is primarily relevant in this medical context.

References

  1. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. (May 2010). "Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs". Science. 328 (5981): 1031–1035. Bibcode:2010Sci...328.1031S. doi:10.1126/science.1183057. PMC   2881692 . PMID   20378772.
  2. Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. (March 2019). "iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer". Nature Communications. 10 (1): 1336. Bibcode:2019NatCo..10.1336D. doi:10.1038/s41467-019-09296-6. PMC   6430780 . PMID   30902997.
  3. 1 2 Ruoslahti E (February 2017). "Tumor penetrating peptides for improved drug delivery". Advanced Drug Delivery Reviews. 110–111: 3–12. doi:10.1016/j.addr.2016.03.008. PMC   5045823 . PMID   27040947.
  4. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (September 2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16157–16162. Bibcode:2009PNAS..10616157T. doi: 10.1073/pnas.0908201106 . PMC   2752543 . PMID   19805273.
  5. Haas MJ (29 April 2010). "Coupled, but not conjugated, in cancer". SciBX: Science-Business EXchange. 3 (17): 514. doi: 10.1038/scibx.2010.514 .
  6. Ruoslahti E (May 2017). "Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier". The Journal of Clinical Investigation. 127 (5): 1622–1624. doi:10.1172/JCI93955. PMC   5409784 . PMID   28414298.
  7. Clinical trial number NCT03517176 for "CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer" at ClinicalTrials.gov
  8. "Cend Therapeutics' CEND-1 Granted Fast Track Designation for Pancreatic Cancer" (Press release). Retrieved 2021-10-01.